Sorrento Therapeutics, Inc. · OTC:SRNE
Sorrento Therapeutics — Presentation (August 2023)
9 slides from Sorrento Therapeutics's investor presentation, Aug 1, 2023
Slide 1: Project Stallion Business Plan Overview
Project Stallion Business Plan Overview July 11, 2023
Slide 2: Disclaimer
Disclaimer 2 This presentation contains selected information pertaining to the business and operations of Sorrento Therapeutics, Inc. (“ Sorrento ” or the “ Company ”). The purpose of this presentation is to assist interested parties in evaluating (i) a potential sale of all or a portion of the Comp
Slide 3: Disclaimer, cont.
Disclaimer, cont. 3 Use of Forecasts This presentation contains financial forecasts or forecasts with respect to Sorrento’s forecasted financial results. Sorrento’s independent auditors have not audited, reviewed, compiled or performed any procedures with respect to the forecasts for the purpose of
Slide 4: Introduction
Introduction 4 (1) EBITDA Contribution is determined before unallocated G&A, Unallocated R&D and restructuring expense Introduction • This presentation contains management’s financial forecast (the “Business Plan”) for reorganized Sorrento (the “Company”) for the period from August 1 2023 through 20
Slide 5: Summary of Key Clinical Development Milestones by Program
Summary of Key Clinical Development Milestones by Program 5 Program Indication Clinical Stage Key clinical development milestones Proj. Commercialization Date Ovydso Phase III • Q3 2023: Database lock and receipt of top line data for 1,200 patient Phase III trial • Q3 2023: Receipt of full clinical
Slide 6: Overview of Key Programs and Near Term Capital Requirements
Overview of Key Programs and Near Term Capital Requirements (1) (2) 6 (1) Not adjusted by Probability of Success (2) Not all IP assets or Potential Programs are included in the business plan; Company has programs that could be licensed to third parties or commercialized with additional capital; mana
Slide 7: Summary Annual Forecast through FYE 2039
Summary Annual Forecast through FYE 2039 (1) (1) Not Adjusted by Probability of Success 7 Aug - Dec FY FY FY FY FY FY FY A v e r a ge ($ MM) 2023 2024 2025 2026 2027 2028 2029 2030 2031 - 203 9 @ Peak Peak Year Revenue Ovydso – $250 . 3 $500 . 8 $574 . 0 $505 . 2 $404 . 1 $282 . 9 $198 . 0 $49 . 3 $
Slide 8: Summary Annual Forecast through FYE 2039 – Probability Adjusted
Summary Annual Forecast through FYE 2039 – Probability Adjusted A ug - D e c FY FY FY FY FY FY FY Average ($ MM) 2023 2024 2025 2026 2027 2028 2029 2030 2031 - 2 Revenue Ovydso – $183 . 1 $366 . 4 $419 . 9 $369 . 5 $295 . 6 $206 . 9 $144.9 RTX – – – – 201 . 8 381 . 5 500 . 8 634 Fujovee – – – – 23 .
Slide 9: 2023 2024 2025 2026 2027 2028 - 2032 Gross Sales ZTLido $ 5,293,917 $
2023 2024 2025 2026 2027 2028 - 2032 Gross Sales ZTLido $ 125,293,917 $ 169,824,599 $ 187,879,450 $ 199,621,812 $ 209,700,892 $ 1,170,214,418 Elyxyb launch Apr 2023 $ 934,176 $ 7,287,766 $ 32,728,563 $ 80,748,245 $ 115,802,097 $ 808,200,876 Gloperba launch Sept 2023 $ 1,463,279 $ 22,582,286 $ 34,424